EG435366 Inhibitors
Chemical inhibitors of EG435366 can achieve functional inhibition through various mechanisms, primarily by targeting cyclin-dependent kinases (CDKs) that are essential for the cell cycle and transcription regulation. Palbociclib, Ribociclib, Abemaciclib, and Trilaciclib share a common mechanism of action by selectively inhibiting CDK4 and CDK6. These enzymes play a pivotal role in facilitating the G1 to S phase transition by phosphorylating the retinoblastoma protein (Rb), which in turn releases E2F transcription factors. The release of E2F is necessary for the transcription of proteins that activate EG435366. Thus, by arresting the cell cycle in the G1 phase, these inhibitors effectively prevent the downstream activation of EG435366.
Other inhibitors such as Flavopiridol, Dinaciclib, SNS-032, Roscovitine (also known as Seliciclib), and Purvalanol A exhibit broader kinase inhibition profiles. Flavopiridol primarily targets CDK9, which is heavily involved in the regulation of transcription elongation. By inhibiting CDK9, Flavopiridol curtails the transcription of short-lived proteins that may play a role in the activation of EG435366. Dinaciclib shows strong inhibition of CDK2, which is another key regulator of cell cycle progression. By inhibiting CDK2, Dinaciclib downregulates the activity of proteins downstream in the signaling cascade, thereby inhibiting the activation of EG435366. SNS-032, Roscovitine, and Seliciclib also target CDK2 and CDK9, among others, disrupting various signaling pathways and cell cycle transitions. This disruption leads to a decrease in the phosphorylation and activation of proteins that would otherwise contribute to the activation of EG435366. Alsterpaullone targets CDK1 and CDK5, and although CDK1's role is more pronounced in the G2/M transition, its inhibition still contributes to the indirect inhibition of EG435366 by preventing cell cycle progression and, hence, the activation of EG435366. Purvalanol A, being a potent inhibitor of CDK1, 2, and 5, operates on a similar principle, obstructing the phosphorylation cascade required for EG435366 activation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib inhibits CDK4/6, which are crucial for cell cycle progression. Inhibition of CDK4/6 halts the cell cycle in the G1 phase, which can prevent the activation of downstream proteins required for cell cycle progression, including EG435366, by preventing the phosphorylation of proteins that release E2F transcription factors necessary for the expression of EG435366. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, similar to Palbociclib. By halting the cell cycle in the G1 phase, the subsequent cascade that would normally lead to the activation of EG435366 is interrupted, thereby functionally inhibiting EG435366. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor. By blocking CDK4/6 activity, Abemaciclib prevents the phosphorylation of retinoblastoma protein, thus inhibiting the release of E2F transcription factors and subsequent expression of proteins that would activate EG435366. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits CDKs, particularly CDK9, which is involved in transcription elongation. By inhibiting CDK9, the transcription of short-lived proteins that may be involved in activating EG435366 is reduced, leading to functional inhibition of EG435366. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib strongly inhibits multiple CDKs, including CDK2, which is involved in cell cycle regulation. Inhibiting CDK2 can reduce the activity of downstream proteins that are required for the activation of EG435366, resulting in its functional inhibition. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is a potent inhibitor of CDK1/5. While CDK1 is mainly involved in the G2/M transition, its inhibition can still lead to an indirect inhibition of EG435366 by preventing the proper activation of proteins in the cell cycle that would subsequently activate EG435366. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is known to inhibit CDK2, 7, and 9. By inhibiting these CDKs, especially CDK9 which is involved in transcription regulation, it can prevent the activation of proteins that are part of the pathway involving EG435366, leading to its functional inhibition. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine inhibits various CDKs, including CDK2, 7, and 9. The inhibition of these kinases can disrupt signaling pathways and the cell cycle, which indirectly leads to the functional inhibition of EG435366 by preventing necessary phosphorylations that activate EG435366. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDK1, 2, and 5. By inhibiting these kinases, it can prevent the phosphorylation and activation of proteins that are upstream of EG435366, leading to its functional inhibition by preventing activation signals from reaching EG435366. | ||||||